Ionis Pharmaceuticals Inc... (IONS)
NASDAQ: IONS
· Real-Time Price · USD
72.39
1.02 (1.43%)
At close: Oct 15, 2025, 3:59 PM
72.31
-0.11%
After-hours: Oct 15, 2025, 07:07 PM EDT
Ionis Pharmaceuticals Revenue by Product
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spinraza | 223.56M | 225.96M | 216.41M | 214.41M | 224.45M | 228.72M | 240.51M | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Spinraza Growth | -1.06% | +4.42% | +0.93% | -4.48% | -1.87% | -4.90% | -2.04% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Wainua | 35.16M | 28.52M | 20.28M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Wainua Growth | +23.26% | +40.67% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Tegsedi and Waylivra | 36.17M | 30.83M | 33.74M | 34.74M | 34.11M | 36.57M | 34.42M | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Tegsedi and Waylivra Growth | +17.32% | -8.63% | -2.88% | +1.87% | -6.74% | +6.25% | +6.17% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
Revenue by Segment
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Commercial | 340.65M | 309.94M | 293.36M | 286.36M | 294.71M | 300.57M | 308.75M | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Commercial Growth | +9.91% | +5.65% | +2.44% | -2.83% | -1.95% | -2.65% | -0.32% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Research and Development | 603.82M | 407.74M | 412.2M | 517.2M | 519.24M | 476.54M | 479.4M | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Research and Development Growth | +48.09% | -1.08% | -20.30% | -0.39% | +8.96% | -0.59% | +56.98% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |